Crf antagonists and heterobicyclic compounds

Details Crf antagonists and heterobicyclic compounds Crf antagonists and heterobicyclic compounds

C - Chemistry, Metallurgy

07

D

C07D 221/04 (2006.01) A61K 31/435 (2006.01) A61K 31/505 (2006.01) A61K 31/517 (2006.01) A61K 31/519 (2006.01) A61K 31/53 (2006.01) C07D 239/16 (2006.01) C07D 239/70 (2006.01) C07D 487/04 (2006.01) C07D 491/048 (2006.01) C07D 513/04 (2006.01)

Patent

CA 2538026

CRF antagonists containing as the active ingredient compounds represented by the general formula (I): (I) wherein A is an optionally substituted 5- or 6- membered monocycle; B is a 5- to 7-membered monocyclic unsaturated heterocycle which may additionally contain one or two heteroatoms and which may be additionally substituted; W1 and W2 are each carbon or nitrogen; Z is NR3, oxygen, optionally oxidized sulfur, or CR4R5; R1 is optionally substituted, alkyl, alkenyl, or alkynyl, optionally protected amino, optionally protected hydroxyl, optionally protected SH, S(O)nR6, COR7, or an optionally substituted cyclic group; and R2 is an unsaturated cyclic group which may be substituted.

L'invention concerne des antagonistes CRF contenant des composés actifs représentés par la formule (I) : (I), dans laquelle A est un monocycle à 5 ou 6 éléments éventuellement substitué, B est un hétérocycle monocyclique insaturé comportant 5 à 7 éléments, cet hétérocycle pouvant également contenir un ou deux hétéroatomes et éventuellement être substitué, W?1¿ et W?2¿ signifient chacun carbone ou azote, Z désigne NR?3¿, oxygène, soufre éventuellement oxydé ou CR?4¿R?5¿, R?1¿ est éventuellement substitué, alkyle, alcényle ou alcynyle, amino éventuellement protégé, hydroxyle éventuellement protégé, SH éventuellement protégé, S(O)¿n?R?6¿, COR?7¿ ou un groupe cyclique éventuellement substitué, R?2¿ représente un groupe cyclique insaturé pouvant être substitué.

Affiliated with

Also associated with

Rating

Crf antagonists and heterobicyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crf antagonists and heterobicyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crf antagonists and heterobicyclic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2086766